Shots:
Saya Biologics has signed a strategic partnership with Kashiv BioSciences to register and commercialize a supportive oncology therapy in Mexico and the CAC region
As per the deal, the agreement spans 11 countries across Mexico and the CAC region. Saya Biologics will handle regulatory registration, commercialization, and distribution, while Kashiv BioSciences will oversee manufacturing and supply.
Saya has already submitted the regulatory dossier in Mexico,…
Shots:
Polpharma Biologics has signed a licensing agreement with Brazil-based Libbs Farmacêutica for an autoimmune biosimilar
Under this strategic partnership, Polpharma Biologics is fully responsible for the development and manufacturing of the product
Libbs will exclusively handle the product’s commercialization, marketing, and distribution in the Brazilian market
Ref: Polpharma Biologics | Image: Polpharma Biologics | Press Release
Related News:- Polpharma Biologics Launches…
Shots:
Bio-Thera Solutions & SteinCares signed an agreement to commercialize a proposed dupilumab biosimilar for inflammatory diseases in Latin America
As per the deal, Bio-Thera will handle product development and supply, while SteinCares manages registration and commercialization in Latin America
Dupilumab (SC) is a fully human mAb that blocks IL-4 and IL-13 signalling pathways and…
Shots:
Brazil’s ANVISA has approved marketing authorization for Formycon’s Ranivisio (ranibizumab), a biosimilar to Lucentis; launch is anticipated in Q4’25
Formycon & Biomm have partnered to commercialize Ranivisio in Latin America, with approvals already granted in Peru, El Salvador, Honduras, and the Dominican Republic. Additional launches across Central and South America are planned through early…

